… Our objective was to evaluate the effectiveness of nirmatrelvir–ritonavir on health outcomes,
including hospital admission and death from COVID-19, while Omicron and its subvariants …

… of Molnupiravir and Nirmatrelvir-ritonavir use in reducing mortality in this population. … % in
the subsequent hospital admissions among 4442 patients with Nirmatrelvir-ritonavir and 28% …

… or did not receive nirmatrelvir-ritonavir within the Kaiser … of nirmatrelvir-ritonavir in
preventing hospital admission or … against intensive care unit admission, mechanical ventilation, …

… In the USA, oral nirmatrelvir–ritonavir is authorised for use in patients aged 12 years or older
… the effectiveness of nirmatrelvir–ritonavir in preventing hospital admissions and death in …

… In this retrospective cohort study, we sought to compare the effectiveness of sotrovimab,
molnupiravir, and nirmatrelvir-ritonavir in preventing hospital admission and death in higher-risk …

… or nirmatrelvir–ritonavir treatment at public hospitals during the … public hospitals in Hong
Kong are managed by the Hospital … , and molnupiravir and nirmatrelvir–ritonavir were equally …

… , SARS-CoV-2 positive test during hospital admission, or being in hospital at the time of
nirmatrelvir–ritonavir order, or discharge on the same date of nirmatrelvir–ritonavir order (n=993), …

… versus nirmatrelvir‐ritonavir group, p = 0.01), and the SARS‐CoV‐2 negative conversion
time and length of hospital stay were significantly shorter in the nirmatrelvir‐ritonavir group than …

… In this publication, WHO made a strong recommendation in favor of nirmatrelvir-ritonavir, for
patients with mild and moderate COVID-19 at high-risk of hospital admission, qualifying it as …

… Hospitalized patients with COVID-19 without oxygen therapy and receiving early (i)
molnupiravir or (ii) nirmatrelvir/ritonavir treatment at public hospitals during the observation period …